CN110248671A - 包含溶瘤痘病毒和nk细胞的治疗剂及其在治疗肿瘤和/或癌症的药物中的应用 - Google Patents
包含溶瘤痘病毒和nk细胞的治疗剂及其在治疗肿瘤和/或癌症的药物中的应用 Download PDFInfo
- Publication number
- CN110248671A CN110248671A CN201880004934.9A CN201880004934A CN110248671A CN 110248671 A CN110248671 A CN 110248671A CN 201880004934 A CN201880004934 A CN 201880004934A CN 110248671 A CN110248671 A CN 110248671A
- Authority
- CN
- China
- Prior art keywords
- cell
- cancer
- dosage
- hours
- rfp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000000822 natural killer cell Anatomy 0.000 title claims abstract description 536
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 182
- 230000000174 oncolytic effect Effects 0.000 title claims abstract description 175
- 239000003814 drug Substances 0.000 title claims abstract description 132
- 201000011510 cancer Diseases 0.000 title claims abstract description 107
- 229940124597 therapeutic agent Drugs 0.000 title claims abstract description 66
- 229940079593 drug Drugs 0.000 title claims abstract description 21
- 238000011282 treatment Methods 0.000 title abstract description 20
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 71
- 239000000470 constituent Substances 0.000 claims abstract description 30
- 210000004027 cell Anatomy 0.000 claims description 412
- 239000008194 pharmaceutical composition Substances 0.000 claims description 103
- 241000700605 Viruses Species 0.000 claims description 94
- 238000000034 method Methods 0.000 claims description 51
- 238000000338 in vitro Methods 0.000 claims description 26
- 230000003321 amplification Effects 0.000 claims description 22
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 22
- 101150004676 VGF gene Proteins 0.000 claims description 20
- 101150003725 TK gene Proteins 0.000 claims description 19
- 230000007812 deficiency Effects 0.000 claims description 18
- 206010009944 Colon cancer Diseases 0.000 claims description 16
- 206010064571 Gene mutation Diseases 0.000 claims description 16
- 238000002347 injection Methods 0.000 claims description 16
- 239000007924 injection Substances 0.000 claims description 16
- 201000007270 liver cancer Diseases 0.000 claims description 16
- 208000014018 liver neoplasm Diseases 0.000 claims description 16
- 201000001441 melanoma Diseases 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 16
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 15
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 15
- 208000019065 cervical carcinoma Diseases 0.000 claims description 15
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 15
- 206010005003 Bladder cancer Diseases 0.000 claims description 14
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 14
- 206010006187 Breast cancer Diseases 0.000 claims description 14
- 208000026310 Breast neoplasm Diseases 0.000 claims description 14
- 208000017897 Carcinoma of esophagus Diseases 0.000 claims description 14
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 14
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 14
- 206010060862 Prostate cancer Diseases 0.000 claims description 14
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 14
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 14
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 14
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 14
- 206010017758 gastric cancer Diseases 0.000 claims description 14
- 210000003734 kidney Anatomy 0.000 claims description 14
- 208000032839 leukemia Diseases 0.000 claims description 14
- 201000005202 lung cancer Diseases 0.000 claims description 14
- 208000020816 lung neoplasm Diseases 0.000 claims description 14
- 210000002751 lymph Anatomy 0.000 claims description 14
- 201000011549 stomach cancer Diseases 0.000 claims description 14
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 14
- 206010046766 uterine cancer Diseases 0.000 claims description 14
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 5
- 206010000496 acne Diseases 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 abstract description 6
- 230000002401 inhibitory effect Effects 0.000 description 235
- 238000002474 experimental method Methods 0.000 description 178
- 244000309459 oncolytic virus Species 0.000 description 149
- 230000000694 effects Effects 0.000 description 142
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 118
- 230000002147 killing effect Effects 0.000 description 118
- 230000000052 comparative effect Effects 0.000 description 70
- 238000012360 testing method Methods 0.000 description 67
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 61
- 239000007788 liquid Substances 0.000 description 52
- 241000701161 unidentified adenovirus Species 0.000 description 43
- 239000012634 fragment Substances 0.000 description 42
- 230000022534 cell killing Effects 0.000 description 39
- 238000007619 statistical method Methods 0.000 description 34
- 230000001225 therapeutic effect Effects 0.000 description 33
- 208000015181 infectious disease Diseases 0.000 description 32
- 230000008859 change Effects 0.000 description 22
- 238000013467 fragmentation Methods 0.000 description 22
- 238000006062 fragmentation reaction Methods 0.000 description 22
- 230000006870 function Effects 0.000 description 22
- 230000004083 survival effect Effects 0.000 description 22
- 238000011534 incubation Methods 0.000 description 20
- 241000282414 Homo sapiens Species 0.000 description 18
- 230000002195 synergetic effect Effects 0.000 description 18
- 239000000890 drug combination Substances 0.000 description 16
- 238000002648 combination therapy Methods 0.000 description 15
- 230000001665 lethal effect Effects 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 239000001963 growth medium Substances 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 10
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 10
- 239000003446 ligand Substances 0.000 description 10
- 230000000259 anti-tumor effect Effects 0.000 description 9
- 230000009194 climbing Effects 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 241000700584 Simplexvirus Species 0.000 description 7
- 238000012239 gene modification Methods 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 241000700618 Vaccinia virus Species 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 101000991061 Homo sapiens MHC class I polypeptide-related sequence B Proteins 0.000 description 4
- 102100030300 MHC class I polypeptide-related sequence B Human genes 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 102000006601 Thymidine Kinase Human genes 0.000 description 4
- 108020004440 Thymidine kinase Proteins 0.000 description 4
- 241000711975 Vesicular stomatitis virus Species 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 230000005017 genetic modification Effects 0.000 description 4
- 235000013617 genetically modified food Nutrition 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000010445 mica Substances 0.000 description 4
- 229910052618 mica group Inorganic materials 0.000 description 4
- 108010054624 red fluorescent protein Proteins 0.000 description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 4
- 241000991587 Enterovirus C Species 0.000 description 3
- 241000175212 Herpesvirales Species 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 101800003344 Vaccinia growth factor Proteins 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 229940126587 biotherapeutics Drugs 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 108700025694 p53 Genes Proteins 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000005909 tumor killing Effects 0.000 description 3
- 210000002845 virion Anatomy 0.000 description 3
- IUVCFHHAEHNCFT-INIZCTEOSA-N 2-[(1s)-1-[4-amino-3-(3-fluoro-4-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=C(F)C(OC(C)C)=CC=C1C(C1=C(N)N=CN=C11)=NN1[C@@H](C)C1=C(C=2C=C(F)C=CC=2)C(=O)C2=CC(F)=CC=C2O1 IUVCFHHAEHNCFT-INIZCTEOSA-N 0.000 description 2
- 241000711404 Avian avulavirus 1 Species 0.000 description 2
- 241000709687 Coxsackievirus Species 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 2
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 2
- 241001135569 Human adenovirus 5 Species 0.000 description 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 2
- 241000712079 Measles morbillivirus Species 0.000 description 2
- 241000702263 Reovirus sp. Species 0.000 description 2
- 241000710961 Semliki Forest virus Species 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000001815 biotherapy Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 230000007541 cellular toxicity Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 108010021843 fluorescent protein 583 Proteins 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000004727 humoral immunity Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000001524 infective effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000003104 tissue culture media Substances 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 241000975394 Evechinus chloroticus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 101001132524 Homo sapiens Retinoic acid early transcript 1E Proteins 0.000 description 1
- 101000760175 Homo sapiens Zinc finger protein 35 Proteins 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 101100508081 Human herpesvirus 1 (strain 17) ICP34.5 gene Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 102100030704 Interleukin-21 Human genes 0.000 description 1
- 241001372913 Maraba virus Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 102100037571 Neurosecretory protein VGF Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 101150027249 RL1 gene Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 102100033964 Retinoic acid early transcript 1E Human genes 0.000 description 1
- 241000837158 Senecavirus A Species 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 102100024672 Zinc finger protein 35 Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000002902 bimodal effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000009096 combination chemotherapy Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000011262 co‐therapy Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000007849 functional defect Effects 0.000 description 1
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 108010074108 interleukin-21 Proteins 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229930192851 perforin Natural products 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011127 radiochemotherapy Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000002476 tumorcidal effect Effects 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/763—Herpes virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/765—Reovirus; Rotavirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/766—Rhabdovirus, e.g. vesicular stomatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/50—Colon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/53—Liver
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/54—Pancreas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/55—Lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
提供了包含溶瘤痘病毒和NK细胞的治疗剂及其在制备治疗肿瘤和/或癌症的药物中的应用。所述治疗剂的活性成分包括溶瘤痘病毒和NK细胞，所述溶瘤痘病毒能够选择性地在肿瘤细胞中复制。
Description
PCT国内申请，说明书已公开。
Claims (37)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2017100039541 | 2017-01-04 | ||
| CN201710003954.1A CN108261426B (zh) | 2017-01-04 | 2017-01-04 | 药物组合物及其在治疗肿瘤和/或癌症的药物中的应用 |
| PCT/CN2018/070172 WO2018127053A1 (zh) | 2017-01-04 | 2018-01-03 | 包含溶瘤痘病毒和nk细胞的治疗剂及其在治疗肿瘤和/或癌症的药物中的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110248671A true CN110248671A (zh) | 2019-09-17 |
| CN110248671B CN110248671B (zh) | 2023-07-04 |
Family
ID=62771609
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710003954.1A Active CN108261426B (zh) | 2017-01-04 | 2017-01-04 | 药物组合物及其在治疗肿瘤和/或癌症的药物中的应用 |
| CN201880004947.6A Active CN110325200B (zh) | 2017-01-04 | 2018-01-03 | 治疗剂及其在治疗肿瘤和/或癌症的药物中的应用 |
| CN201880004934.9A Active CN110248671B (zh) | 2017-01-04 | 2018-01-03 | 包含溶瘤痘病毒和nk细胞的治疗剂及其在治疗肿瘤和/或癌症的药物中的应用 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710003954.1A Active CN108261426B (zh) | 2017-01-04 | 2017-01-04 | 药物组合物及其在治疗肿瘤和/或癌症的药物中的应用 |
| CN201880004947.6A Active CN110325200B (zh) | 2017-01-04 | 2018-01-03 | 治疗剂及其在治疗肿瘤和/或癌症的药物中的应用 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US11446345B2 (zh) |
| EP (2) | EP3566709A4 (zh) |
| JP (2) | JP7239911B2 (zh) |
| CN (3) | CN108261426B (zh) |
| WO (2) | WO2018127053A1 (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110325200A (zh) * | 2017-01-04 | 2019-10-11 | 杭州康万达医药科技有限公司 | 治疗剂及其在治疗肿瘤和/或癌症的药物中的应用 |
| CN114569708A (zh) * | 2020-12-02 | 2022-06-03 | 四川大学华西医院 | Nkg2d car-免疫细胞在抗衰老中应用 |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109022374B (zh) * | 2018-08-16 | 2021-05-14 | 华中农业大学 | 一种塞内卡谷病毒重组质粒、重组病毒及构建方法 |
| CN110856751A (zh) * | 2018-08-24 | 2020-03-03 | 合成免疫股份有限公司 | 包含核酸及tcr修饰的免疫细胞的治疗剂及其应用 |
| CN111110706A (zh) * | 2018-10-30 | 2020-05-08 | 中国科学院武汉病毒研究所 | 肠道病毒71型在制备溶瘤药物中的应用 |
| CN113840914A (zh) * | 2019-05-14 | 2021-12-24 | 国立大学法人鸟取大学 | 诱导细胞融合的痘苗病毒及其应用 |
Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070077231A1 (en) * | 2005-09-30 | 2007-04-05 | Contag Christopher H | Immune effector cells pre-infected with oncolytic virus |
| CN105307671A (zh) * | 2013-04-18 | 2016-02-03 | 蒂尔坦生物制药有限公司 | 增强过继细胞疗法 |
| CN108261426A (zh) * | 2017-01-04 | 2018-07-10 | 杭州康万达医药科技有限公司 | 药物组合物及其在治疗肿瘤和/或癌症的药物中的应用 |
| CN108338994A (zh) * | 2017-01-25 | 2018-07-31 | 杭州康万达医药科技有限公司 | 溶瘤病毒作为用于治疗肿瘤和/或癌症的免疫刺激剂的应用 |
| CN109554353A (zh) * | 2017-09-26 | 2019-04-02 | 杭州康万达医药科技有限公司 | 分离的重组溶瘤痘病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途 |
| WO2019062250A1 (zh) * | 2017-09-28 | 2019-04-04 | 杭州康万达医药科技有限公司 | 包含分离的重组溶瘤腺病毒和nk细胞的治疗剂及应用、药盒、治疗肿瘤和/或癌症的方法 |
| WO2019133847A1 (en) * | 2017-12-29 | 2019-07-04 | Oncorus, Inc. | Oncolytic viral delivery of therapeutic polypeptides |
| CN111743923A (zh) * | 2019-03-27 | 2020-10-09 | 北京康万达医药科技有限公司 | 包含分离的重组溶瘤腺病毒和免疫细胞的治疗剂及其应用 |
| WO2021159035A1 (en) * | 2020-02-07 | 2021-08-12 | City Of Hope | Oncolytic virus compositions and methods for the treatment of cancer |
| CN113583977A (zh) * | 2020-04-30 | 2021-11-02 | 杭州康万达医药科技有限公司 | 可受微小rna调控的分离的重组溶瘤痘病毒及其应用 |
| CN114072416A (zh) * | 2019-02-18 | 2022-02-18 | 克里尔治疗股份有限公司 | 使用正痘病毒主要组织相容性复合物（mhc）i类样蛋白（omcp）和肿瘤特异性结合伴侣的双特异性融合蛋白 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2379586T1 (sl) * | 2008-12-22 | 2017-02-28 | Targovax Oy | Onkolitični adenovirusni vektorji in z njimi povezani postopki in uporabe |
| FI20090030A0 (fi) * | 2009-02-02 | 2009-02-02 | Akseli Eetu Hemminki | Onkolyyttiset virukset |
| BR112013017096A2 (pt) | 2011-01-04 | 2020-09-01 | Jennerex Inc. | composição e métodos de indução de resposta citotóxica dependente de complemento mediado por anticorpo específico de tumor em animal tendo tumor, de geração de anticorpos in vivo, de inibição do crescimento ou morte de célula de câncer, para tratar indivíduo com câncer, para adaptar de terapia de câncer para indivíduo com câncer e para identificar antígeno específico de tumor |
| US10238700B2 (en) | 2014-01-02 | 2019-03-26 | Genelux Corporation | Oncolytic virus adjunct therapy with agents that increase virus infectivity |
| PL3169341T3 (pl) * | 2014-07-16 | 2019-12-31 | Transgene Sa | Wirus onkolityczny do ekspresji modulatorów punktu kontroli immunologicznej |
| CA2955084C (en) | 2014-07-16 | 2023-08-29 | Transgene Sa | Combination of oncolytic virus with immune checkpoint modulators |
| SG11201707541WA (en) * | 2015-03-17 | 2017-10-30 | Tilt Biotherapeutics Oy | Oncolytic adenoviruses coding for bi-specific antibodies and methods and uses related thereto |
| CA2981979A1 (en) | 2015-04-06 | 2016-10-13 | Jianhua Yu | Egfr-directed car therapy for glioblastoma |
| BR112018013930A2 (pt) * | 2016-01-08 | 2018-12-11 | Replimune Limited | vírus oncolítico, vírus que expressa três genes heterólogos, composição farmacêutica, vírus para o uso, produto de fabricação, método de tratamento de câncer e uso do vírus |
| CN106177961B (zh) | 2016-08-18 | 2018-03-13 | 广州威溶特医药科技有限公司 | Vcp抑制剂和溶瘤病毒在制备抗肿瘤药物中的应用 |
| EP3526278B1 (en) | 2016-10-11 | 2020-12-30 | Alcon Inc. | Chain-extended polydimethylsiloxane vinylic crosslinkers and uses thereof |
| JP7173495B2 (ja) | 2016-11-04 | 2022-11-16 | セントロ デ インベスティガシオン ビオメディカ エン レッド | 敗血症又は敗血症性ショック（ｓｓ）患者に由来する血漿中の循環ヒストンｈ３及びｈ２ｂを検出する質量分析ベースの方法 |
| EP3916098A1 (en) * | 2020-05-25 | 2021-12-01 | Medizinische Hochschule Hannover | Adenovirus for anti-tumour therapy |
| CN114657150A (zh) * | 2020-12-23 | 2022-06-24 | 北京康万达医药科技有限公司 | 用于改善免疫疗法的重组溶瘤腺病毒及其应用 |
-
2017
- 2017-01-04 CN CN201710003954.1A patent/CN108261426B/zh active Active
-
2018
- 2018-01-03 JP JP2019536075A patent/JP7239911B2/ja active Active
- 2018-01-03 EP EP18736087.0A patent/EP3566709A4/en active Pending
- 2018-01-03 US US16/474,349 patent/US11446345B2/en active Active
- 2018-01-03 US US16/474,353 patent/US20190343881A1/en active Pending
- 2018-01-03 WO PCT/CN2018/070172 patent/WO2018127053A1/zh unknown
- 2018-01-03 EP EP18736473.2A patent/EP3566710A4/en active Pending
- 2018-01-03 CN CN201880004947.6A patent/CN110325200B/zh active Active
- 2018-01-03 CN CN201880004934.9A patent/CN110248671B/zh active Active
- 2018-01-03 WO PCT/CN2018/070166 patent/WO2018127052A1/zh unknown
- 2018-01-03 JP JP2019536062A patent/JP7239910B2/ja active Active
-
2022
- 2022-07-07 US US17/859,564 patent/US20220339220A1/en active Pending
Patent Citations (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070077231A1 (en) * | 2005-09-30 | 2007-04-05 | Contag Christopher H | Immune effector cells pre-infected with oncolytic virus |
| CN105307671A (zh) * | 2013-04-18 | 2016-02-03 | 蒂尔坦生物制药有限公司 | 增强过继细胞疗法 |
| CN110325200A (zh) * | 2017-01-04 | 2019-10-11 | 杭州康万达医药科技有限公司 | 治疗剂及其在治疗肿瘤和/或癌症的药物中的应用 |
| CN108261426A (zh) * | 2017-01-04 | 2018-07-10 | 杭州康万达医药科技有限公司 | 药物组合物及其在治疗肿瘤和/或癌症的药物中的应用 |
| JP2020503344A (ja) * | 2017-01-04 | 2020-01-30 | ハンジョウ・コンバード・カンパニー, リミテッドHangzhou Converd Co., Ltd | 腫瘍溶解性ワクシニアウイルスおよびｎｋ細胞を含む治療剤、ならびに腫瘍および／またはがんの治療のための薬物のためのその使用 |
| EP3566709A1 (en) * | 2017-01-04 | 2019-11-13 | Hangzhou Converd Co., Ltd. | Therapeutic agent comprising oncolytic viruses and nk cells and application thereof in drugs for treating tumors and/or cancer |
| US20190336549A1 (en) * | 2017-01-04 | 2019-11-07 | Hangzhou Converd Co., Ltd. | Therapeutic agents and uses thereof for drugs for treatment of tumors and/or cancers |
| CN108338994A (zh) * | 2017-01-25 | 2018-07-31 | 杭州康万达医药科技有限公司 | 溶瘤病毒作为用于治疗肿瘤和/或癌症的免疫刺激剂的应用 |
| CN109554353A (zh) * | 2017-09-26 | 2019-04-02 | 杭州康万达医药科技有限公司 | 分离的重组溶瘤痘病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途 |
| WO2019062233A1 (zh) * | 2017-09-26 | 2019-04-04 | 杭州康万达医药科技有限公司 | 包含分离的重组溶瘤痘病毒和nk细胞的治疗剂及应用、药盒、治疗肿瘤和/或癌症的方法 |
| WO2019062250A1 (zh) * | 2017-09-28 | 2019-04-04 | 杭州康万达医药科技有限公司 | 包含分离的重组溶瘤腺病毒和nk细胞的治疗剂及应用、药盒、治疗肿瘤和/或癌症的方法 |
| CN111344398A (zh) * | 2017-09-28 | 2020-06-26 | 杭州康万达医药科技有限公司 | 分离的重组溶瘤腺病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途 |
| WO2019133847A1 (en) * | 2017-12-29 | 2019-07-04 | Oncorus, Inc. | Oncolytic viral delivery of therapeutic polypeptides |
| CN114072416A (zh) * | 2019-02-18 | 2022-02-18 | 克里尔治疗股份有限公司 | 使用正痘病毒主要组织相容性复合物（mhc）i类样蛋白（omcp）和肿瘤特异性结合伴侣的双特异性融合蛋白 |
| CN111743923A (zh) * | 2019-03-27 | 2020-10-09 | 北京康万达医药科技有限公司 | 包含分离的重组溶瘤腺病毒和免疫细胞的治疗剂及其应用 |
| WO2021159035A1 (en) * | 2020-02-07 | 2021-08-12 | City Of Hope | Oncolytic virus compositions and methods for the treatment of cancer |
| CN113583977A (zh) * | 2020-04-30 | 2021-11-02 | 杭州康万达医药科技有限公司 | 可受微小rna调控的分离的重组溶瘤痘病毒及其应用 |
| WO2021218802A1 (zh) * | 2020-04-30 | 2021-11-04 | 杭州康万达医药科技有限公司 | 可受微小rna调控的分离的重组溶瘤痘病毒及其应用 |
Non-Patent Citations (11)
| Title |
|---|
| ANGELICA P. ASPIRIN等: "Polytherapeutic strategies with oncolytic virus–bortezomib and adjuvant NK cells in cancer treatment", 《J. R. SOC. INTERFACE》 * |
| ANGELICA P. ASPIRIN等: "Polytherapeutic strategies with oncolytic virus–bortezomib and adjuvant NK cells in cancer treatment", 《J. R. SOC. INTERFACE》, vol. 18, 6 January 2021 (2021-01-06), pages 1 - 13 * |
| ELAINE Y. L. LEUNG等: "Strategies to Optimise Oncolytic Viral Therapies: The Role of Natural Killer Cells", 《VIRUS》 * |
| ELAINE Y. L. LEUNG等: "Strategies to Optimise Oncolytic Viral Therapies: The Role of Natural Killer Cells", 《VIRUS》, vol. 13, no. 1450, 26 July 2021 (2021-07-26), pages 1 - 12 * |
| 刘耕陶主编: "《当代药理学》", 31 May 2008, 中国协和医科大学出版社, pages: 274 - 276 * |
| 喻启桂;: "肿瘤治疗的新突破:溶瘤病毒治疗", 安徽医药, no. 01, pages 1 - 7 * |
| 崔姣艳等: "溶瘤病毒联合其他药物用于肿瘤治疗的研究进展", 《中国新药杂志》 * |
| 崔姣艳等: "溶瘤病毒联合其他药物用于肿瘤治疗的研究进展", 《中国新药杂志》, vol. 30, no. 3, 15 March 2021 (2021-03-15), pages 246 - 253 * |
| 张思汗等: "肿瘤免疫治疗药物的开发现状及展望", 《临床与病理杂志》 * |
| 张思汗等: "肿瘤免疫治疗药物的开发现状及展望", 《临床与病理杂志》, vol. 41, no. 10, 28 October 2021 (2021-10-28), pages 2447 - 2460 * |
| 贾晓渊;郭彦孜;: "溶瘤痘苗病毒对肿瘤细胞作用机制的研究进展", 中国科学:生命科学, no. 04, pages 414 - 422 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110325200A (zh) * | 2017-01-04 | 2019-10-11 | 杭州康万达医药科技有限公司 | 治疗剂及其在治疗肿瘤和/或癌症的药物中的应用 |
| CN114569708A (zh) * | 2020-12-02 | 2022-06-03 | 四川大学华西医院 | Nkg2d car-免疫细胞在抗衰老中应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP7239911B2 (ja) | 2023-03-15 |
| WO2018127053A1 (zh) | 2018-07-12 |
| EP3566710A1 (en) | 2019-11-13 |
| US20190336549A1 (en) | 2019-11-07 |
| EP3566709A1 (en) | 2019-11-13 |
| EP3566710A4 (en) | 2020-12-09 |
| CN110325200B (zh) | 2023-07-04 |
| CN108261426B (zh) | 2019-04-05 |
| JP2020503343A (ja) | 2020-01-30 |
| CN110248671B (zh) | 2023-07-04 |
| US11446345B2 (en) | 2022-09-20 |
| CN108261426A (zh) | 2018-07-10 |
| JP2020503344A (ja) | 2020-01-30 |
| US20220339220A1 (en) | 2022-10-27 |
| WO2018127052A1 (zh) | 2018-07-12 |
| US20190343881A1 (en) | 2019-11-14 |
| EP3566709A4 (en) | 2020-07-29 |
| JP7239910B2 (ja) | 2023-03-15 |
| CN110325200A (zh) | 2019-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110248671A (zh) | 包含溶瘤痘病毒和nk细胞的治疗剂及其在治疗肿瘤和/或癌症的药物中的应用 | |
| CN110128550B (zh) | 一种新型的同时阻断免疫检查点pd-l1和tigit的复制型溶瘤腺病毒和应用 | |
| US11806374B2 (en) | Isolated recombinant oncolytic adenoviruses, pharmaceutical compositions, and uses thereof for drugs for treatment of tumors and/or cancers | |
| CN111315873B (zh) | 分离的重组溶瘤痘病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途 | |
| CN105658795A (zh) | 免疫溶瘤疗法 | |
| CN110982794B (zh) | 一种修饰的单纯疱疹病毒 | |
| EP3778882A1 (en) | Recombinant oncolytic virus composition and use thereof | |
| WO2019080537A1 (zh) | 包含溶瘤病毒和car-nk细胞的治疗剂及应用、药盒、治疗肿瘤和/或癌症的方法 | |
| CN111467489A (zh) | 一种治疗肿瘤的药物 | |
| CN103614416A (zh) | 一种携带人穿膜肽p53与GM-CSF基因的重组溶瘤腺病毒及其用途 | |
| CN110305198A (zh) | 一种溶瘤棒状病毒减毒株及其在肿瘤治疗中的应用 | |
| CN111606999B (zh) | 兼具激活免疫共刺激信号通路和阻断免疫检查点的复制型溶瘤腺病毒及其应用 | |
| WO2020233102A1 (zh) | 一种治疗肿瘤或癌症的药物组合物和其应用 | |
| CN106978397A (zh) | 一种人dc-cik免疫活性细胞及其制备方法 | |
| JP2004529158A (ja) | 混成殺腫瘍ヘルペスウイルスベクター |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40011177 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |